Evidence map›Paper›PMID 38932424›Full record

ArticleVaccines2024

Progress and Challenges in Measles and Rubella Elimination in the WHO European Region.

Mark Muscat, Myriam Ben Mamou, Catharina Reynen-de Kat, Dragan Jankovic, José Hagan, Simarjit Singh, Siddhartha Sankar Datta

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Trend of Measles Outbreak in Yemen From January 2020 to August 2024.International journal of general medicine · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mark MuscatVaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-0468-7618
Myriam Ben MamouVaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.
Catharina Reynen-de KatVaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.
Dragan JankovicVaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.
José HaganVaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-1837-6319
Simarjit SinghVaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.
Siddhartha Sankar DattaVaccine-Preventable Diseases and Immunization Programme, World Health Organization Regional Office for Europe, DK-2100 Copenhagen, Denmark.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The elimination of both measles and rubella remains a priority for all 53 Member States of the World Health Organization (WHO) European Region. To provide an update on the epidemiological status of measles and rubella in the Region, we reviewed surveillance data on both diseases for 2023 submitted monthly by national surveillance institutions. We analyzed the cases of measles and rubella for 2023 by age group, case classification, vaccination, hospitalization, and importation status and report on measles-related deaths. In 2023, 60,860 measles cases, including 13 fatal cases, were reported in 41 countries. Most cases (95%; n = 57,584) were reported by six countries: Azerbaijan, Kazakhstan, Kyrgyzstan, Romania, the Russian Federation, and Türkiye. Of the 60,848 cases with data on age, 19,137 (31%) were 1-4 years old and 12,838 (21%) were 5-9 years old. A total of 10,412 (17%) were 20 years and older. The genotypes identified in the Region were largely dominated by D8 variants (n = 1357) and the remainder were B3 variants (n = 221). In 2023, 345 rubella cases were reported by 17 countries, mostly from Poland, Kyrgyzstan, Tajikistan, Türkiye, and Ukraine. A total of 262 cases (76%) were classified as clinically compatible and 79 (23%) were laboratory-confirmed. To achieve the elimination of measles and rubella in the Region, political commitment needs to be revived to enable urgent efforts to increase vaccination coverage, improve surveillance and outbreak preparedness, and respond immediately to outbreaks.

Indexed as

disease eliminationdisease outbreaksepidemiologyEuropean regionmeaslespublic health surveillancerubellavaccinesverification

Identifiers

PMID38932424
PMCPMC11209032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.